Navigation Links
Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
Date:11/12/2008

SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today that the company has completed enrollment of subjects in a Phase 2 trial of its therapeutic DNA vaccine designed to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed stem cell transplant recipients. An interim analysis of immunogenicity data for the first 33 transplant recipients in the recipient-only arm of the study showed significant (p<0.05) post-transplant enhancement of CMV-specific T-cell responses in subjects receiving vaccine compared with subjects receiving placebo.

"These patients are highly immunosuppressed after transplant and, due to pre-existing infection, are at risk of CMV reactivation and the associated disease," said Ronald B. Moss, M.D., Vical's Vice President of Clinical Development. "The inducement of CMV-specific T-cell responses after transplant is encouraging, as others have noted that T-cell responses may be predictive of better control of CMV reactivation and disease. These encouraging immunogenicity data should translate into clinical benefit, and should be confirmed by clinical efficacy results in the second quarter of 2009."

The company conducted an interim immunogenicity analysis on post-transplant sera from the first 47 stem cell transplant recipients (33 in the recipient-only arm and 14 in the donor-recipient arm). The resulting data were analyzed by treatment group, but clinical sites and trial participants remain blinded to individual treatment codes. The results indicated significant enhancement of CMV-specific immunity in the recipient-only arm as measured by T-cell responses to the two CMV antigens targeted by the vaccine: pp65 (p<0.05) and gB (p<0.05). Results for the
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
2. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
3. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
4. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
6. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
7. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
8. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
9. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
10. Promise of Vicals CMV Vaccine Noted by Independent Experts
11. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... TB Alliance, a not-for-profit with the ... affordable treatments, announced the appointment of Willo ... Mr. Brock comes to TB Alliance having most ... for WWF International (formerly known as the World ... guide the TB Alliance,s resource development, advocacy and ...
(Date:7/31/2014)... NEW YORK und KISSING, Deutschland, ... ein Hersteller und Distributor eines computerunterstützten („robotischen") ... Nachum (Homi) Shamir , ein weltweit ... seines Leitungs- und Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener ...
(Date:7/31/2014)... Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" or ... branded consumer products, including commercially cultivated Cordyceps Militaris ("Cordyceps"), ... the signing of its first distributor for its new ... Hubei Province located in ... . The contract with the new ...
Breaking Medicine Technology:TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... 14, 2012  Nephros, Inc. (OTC Bulletin Board: ... filtration products for therapeutic applications, infection control, and water ... Sullivan as Director of U.S. Sales. Mr. ... leadership role in the healthcare, life science and biopharmaceutical ...
... HealthCare Pharmaceuticals Inc. today announced that the U.S. Food ... for Natazia® (estradiol valerate and estradiol valerate/dienogest) tablets for ... not caused by any diagnosed conditions of the uterus ... for contraception.  With this approval, Natazia is the first ...
Cached Medicine Technology:Nephros Hires Director of U.S. Sales 2Nephros Hires Director of U.S. Sales 3Nephros Hires Director of U.S. Sales 4Nephros Hires Director of U.S. Sales 5Nephros Hires Director of U.S. Sales 6U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 2U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 3U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) 4
(Date:7/31/2014)... of adults with ADHD improve when their ADHD ... College of Medicine researchers., At least 25 percent ... a parent with ADHD. , "Parents with ADHD ... parenting techniques, including inconsistent disciplinary practices, making ineffectual ... Waxmonsky, associate professor of psychiatry. "Having a parent ...
(Date:7/31/2014)... 2014 Jacuzzi Luxury Bath, ... has launched a new and improved website to meet ... The Jacuzzi Luxury Bath website has been redesigned to ... and quality represented by the company’s products. The design ... and inspirational bathroom applications. “The site reflects our Jacuzzi® ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and Purification ... bead based), Consumables & Instruments, by Application (Plasmid ... users - Global Forecasts to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... with the estimates and forecasts of the revenue ...
(Date:7/31/2014)... Long associated with enabling the proliferation of ... by Heat-Shock Factor 1 (HSF1) can also turn ... support malignant progression and metastasis. , The finding, ... the journal Cell , lends new insights ... diagnosis, prognosis, and management of cancer patients. ...
(Date:7/31/2014)... According to a new market report ... Market - Global Forecast, Market Share, Size, Growth and ... fixation devices market is estimated at USD 6.1 billion ... CAGR of 7.2% from 2014 to 2019, to reach ... Globally, the orthopedic trauma fixation devices market is witnessing ...
Breaking Medicine News(10 mins):Health News:Parenting skills improve in ADHD parents with medication 2Health News:Jacuzzi Luxury Bath Launches New and Improved Website 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 3Health News:Orthopedic Trauma Fixation Devices Market: Global Forecast, Share, Size, Growth and Industry Analysis 2014 - 2020 2Health News:Orthopedic Trauma Fixation Devices Market: Global Forecast, Share, Size, Growth and Industry Analysis 2014 - 2020 3
... Allows Pharmaceutical Brand Managers to Build Patient-Flow Models ... Decision Resources, one of the world,s leading ... healthcare issues, finds that use of Novartis, Diovan ... Cozaar is influenced by physician perception that the ...
... Pharmaceutical Research and Manufacturers of America (PhRMA) President and ... a new healthcare reform coalition:"PhRMA echoes the sentiment shared ... is critical for all Americans to have access to ... central goal in mind, we are working with a ...
... stroke specialists, especially in rural or other underserved areas; ... a "mini" or "warning" stroke, should be treated with ... two separate scientific statements and a policy statement published ... Association . , Telemedicine Statement Highlights: , ...
... May 11 David Cornfield, MD, the chief ... Lucile Packard Children,s Hospital at Stanford, has been ... (SPR).(Photo: http://www.newscom.com/cgi-bin/prnh/20090511/SF14213 )Beginning this month, Cornfield ... pediatricians for a one-year term. "It,s a great ...
... WASHINGTON, May 11 President Obama and U.S. Senate ... protection laws as suggested by health insurers last week, ... said Consumer Watchdog in a letter to the president ... every state over the last 10 years were made ...
... run on behalf of 1.275 million Americans living with spinal ... Dana Reeve Foundation today announced Matthew Reeve, son of Christopher ... Reeve Foundation, will run the 2009 ING New York City ... inspired to compete on behalf of the 1.275 million Americans ...
Cached Medicine News:Health News:More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro 2Health News:More Patients Receive Diovan As A First- Or Second-Line Therapy Compared With Cozaar or Avapro 3Health News:PhRMA Statement on Healthcare Reform Coalition 2Health News:PhRMA Statement on Healthcare Reform Coalition 3Health News:PhRMA Statement on Healthcare Reform Coalition 4Health News:Videoconferencing can increase patient access to stroke specialists 2Health News:Videoconferencing can increase patient access to stroke specialists 3Health News:Packard/Stanford Physician to Lead Society for Pediatric Research 2Health News:President Obama, Sens. Kennedy & Baucus: Don't Buy Insurer 'Compromise' for Bush-era Plan to Gut State Consumer Protection Laws 2Health News:President Obama, Sens. Kennedy & Baucus: Don't Buy Insurer 'Compromise' for Bush-era Plan to Gut State Consumer Protection Laws 3Health News:Matthew Reeve to Run 2009 ING New York City Marathon for Team Reeve 2Health News:Matthew Reeve to Run 2009 ING New York City Marathon for Team Reeve 3
... Package is a solid solution ... The package includes the Vibratome ... mounting blocks, v-block adapter, specimen ... rotating stage assembly for ease ...
... Professional Package is the best ... laboratory. The package includes the ... additional mounting blocks, v-block adapter, ... a sapphire blade for the ...
... Vibratome 3000 Plus Sectioning System provides a ... animal, or plant tissues. The 3000 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
... System provides a versatile means of sectioning ... The 1500 employs a vibrating blade ... embedding. The creation of artifacts, the ... activities, and other deleterious effect inherent in ...
Medicine Products: